Stockreport

DS3610 Enters Clinical Development in Patients with Advanced Solid Tumors as First STING Agonist ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo [Yahoo! Finance]

DAIICHI SANKYO S/ADR  (DSNKY) 
PDF first-in-human phase 1 trial evaluating DS3610 in patients with advanced, metastatic or unresectable solid tumors. DS3610 is an investigational STING agonist antibody [Read more]